74733-28-1

Basic information

• Product Name: Methyl 4-(bromomethyl)-2-methylbenzoate
• Synonyms: Methyl 4-(bromomethyl)-2-methylbenzoate
• CAS NO: 74733-28-1
• Molecular Formula: C₁₀H₁₁BrO₂
• Molecular Weight: 243.09714
• Mol File: 74733-28-1.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 295.6±28.0 °C(Predicted)
• Appearance: /
• Density: 1.404±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Methyl 4-(bromomethyl)-2-methylbenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-(bromomethyl)-2-methylbenzoate(74733-28-1)
• EPA Substance Registry System: Methyl 4-(bromomethyl)-2-methylbenzoate(74733-28-1)

Safety Data

• Hazardous Substances Data: 74733-28-1(Hazardous Substances Data)

Usage

General Description

Methyl 4-(bromomethyl)-2-methylbenzoate is a chemical compound with the molecular formula C10H11BrO2. It is a derivative of benzoic acid and belongs to the ester group. Methyl 4-(bromomethyl)-2-methylbenzoate consists of a benzene ring substituted with a bromomethyl group and a methyl group. It is commonly used in organic synthesis and pharmaceutical research as a building block for the synthesis of various compounds. Its bromomethyl group makes it reactive and suitable for cross-coupling reactions, making it a valuable intermediate in the production of various pharmaceuticals and chemical products.

Upstream product

• 21900-42-5 2,4-dimethylbenzoyl chloride 
• 23617-71-2 2,4-dimethyl-benzoic acid methyl ester 
• 530145-28-9 methyl 4-(hydroxymethyl)-2-methylbenzoate 
• 67-56-1 methanol 
• 611-01-8 2,4-dimethyl-benzoic acid 

Downstream Products

• 861555-67-1 4-(hydroxymethyl)-2-methylbenzoic acid 
• 133052-57-0 methyl-4-[(2-butyl-1H-benzimidazol-1-yl)methyl]-2-methylbenzoate 
• 71441-11-7 4-carboethoxy-3-methylbenzaldehyde 
• 77837-67-3 1-(4-carboethoxy-3-methylphenyl)-2-methyl-1-propene 
• 77837-80-0 4-((E)-3-Hydroxy-2-methyl-propenyl)-2-methyl-benzoic acid ethyl ester 
• 77837-69-5 (E)-3-(4-carboethoxy-3-methylphenyl)-2-methylpropenal 
• 77837-63-9 (1E,3E)-1-(4-carboxy-3-methylphenyl)-2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1,3-butadiene 
• 77837-64-0 (1Z,3E)-1-(4-carboethoxy-3-methylphenyl)-2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1,3-butadiene 
• 77837-62-8 (1E,3E)-1-(4-carboethoxy-3-methylphenyl)-2-methyl-4-(2,6,6-trimethyl-1-cyclohexen-1-yl)-1,3-butadiene 
• 133052-40-1 4-[(2-butyl-1H-benzimidazol-1-yl)methyl]-2-methylbenzoic acid 
• 1268243-58-8 methyl 2-methyl-4-(methylsulfonylmethyl)benzoate 
• 1398397-78-8 methyl 4-((2-(2-(((R)-1-(naphthalen-1-yl)ethyl)amino)ethyl)morpholino)methyl)benzoate 
• 1398397-72-2 methyl 4-((2-(2-(((R)-1-(naphthalen-1-yl)ethyl)amino)ethyl)morpholino)methyl)benzoate 

Relevant articles and documents

A Dual Modulator of Farnesoid X Receptor and Soluble Epoxide Hydrolase to Counter Nonalcoholic Steatohepatitis

Nonalcoholic steatohepatitis arising from Western diet and lifestyle is characterized by accumulation of fat in liver causing inflammation and fibrosis. It evolves as serious health burden with alarming incidence, but there is no satisfying pharmacological therapy to date. Considering the disease's multifactorial nature, modulation of multiple targets might provide superior therapeutic efficacy. In particular, farnesoid X receptor (FXR) activation that revealed antisteatotic and antifibrotic effects in clinical trials combined with inhibition of soluble epoxide hydrolase (sEH) as anti-inflammatory strategy promises synergies. To exploit this dual concept, we developed agents exerting partial FXR agonism and sEH inhibitory activity. Merging known pharmacophores and systematic exploration of the structure-activity relationship on both targets produced dual modulators with low nanomolar potency. Extensive in vitro characterization confirmed high dual efficacy in cellular context combined with low toxicity, and pilot in vivo data revealed favorable pharmacokinetics as well as engagement on both targets in vivo.

Mild Benzylic Monobromination of Methyl Toluates in Aqueous CTAB

A strategy has been developed for the regioselective monobromination of methyl toluates by using tert-butylhydrogen peroxide and potassium bromide (TBHP/KBr) in a cetyltrimethylammonium bromide (CTAB) micellar medium. Ultrasonic and microwave-assisted protocols recorded increased rates and product yields under mild reaction conditions, coupled with a straightforward isolation procedure.

Pyridyl inhibitors of hedgehog signalling

The invention provides novel inhibitors of hedgehog signaling that are useful as a therapeutic agents for treating malignancies where the compounds have the general formula I: wherein A, X, Y R1, R2, R3, R4, m and n are as described herein.